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CDKN2A is a melanoma susceptibility gene that is 
mutated and/or deleted in familial and sporadic mel-
anoma as well as in a range of other tumors. It 
encodes a cell cycle regulator, p16, whose function is 
to inhibit activity of cyclin- dependent kinases 4 and 
6. We set out to investigate the effect of reintroduc-
ing CDKN2A into MM96L, a melanoma cell line that 
does not express p16, by electroporation of wt 
CDKN2A eDNA. Our results show that transfection 
of the CDKN2A eDNA has a dramatic effect on cell 
morphology, inducing a more dendritic phenotype 
resembling that of adult melanocytes. This effect on 
cell morphology was not cell line specific because it 
was reproduced in another melanoma line (SK-MEL-
13), which has a homozygous deletion of CDKN2A. It 
was abolished by mu~ations that abrogate p16 func-
T he CD KN2A gene maps to ch romosome 9p21- 22 (Kamb et a/, 1994a; Nobori et a/, 1994) where a m elanoma susceptibility gene had been localized (C annon-Albright et al, 1992). T he CDKN2A gen e product, known as p16, had previously been identi-
fied as a cyclin-dependent kinase- 4 (CDK4)-bi.nding protein (Ser-
rano et al, 1993) and binds specifically to C DK4 and CDK6 both in 
vitro and i11 vivo, inillbiting their kinase activi ty (Lukas et al, 1995) . 
T hese CDKs bind preferentially to D - type cyclins (Matsu'shime et 
a/, 1994) and afl:ix t essential steps in Gl to S phase progression in 
the ce11 cycle (Baldin eta/, 1993) . Cyclin D-CDK complexes in uitt'o 
can phosphorylate the gen e product of RB1 (pR.B) and inactivate 
its inhibitory function on the G1 to S transition (review ed in Sherr, 
1994) . CDKN 2A therefore has an inhibitory effect on passage fi'om 
G1 to S phase (Schulze eta/, 1994; Lukas et al, 1995). W e have 
recently found that increased levels o fp1 6 induced by low doses of 
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tion, as shown by transfection of a Pro81Leu p16 
variant. Reintroduction oflevels ofp16 protein sim-
ilar to those of cultured neonatal foreskin melano-
cytes decreased the growth rate of the transfected 
clones . Surprisingly, we did not see any effect on 
anchorage-inde'pendent growth or on the following 
melanoma markers tested by western blotting: p21/ 
WAFt, tyrosinase-related antigen 1, HMB45, and 
intermediate filament antigen. These data indicate 
that reintroduction into melanoma c ells of w ild type 
p16 at levels similar to cultured melanocytes can 
induce morp~·wlogic changes and suppress growth 
but is not su~cient to affect anchorage-independent 
growth. Key words: p16/tJ'ansfection/melanoma-associated 
markers.] Invest Dermatol 109:61-68, 1997 
ultraviol e t radiation correlated with a G2 delay, suggesting that p16 
may also regulate a ch eckpoint at tllis later phase of the cell cycle 
(Wang et a!, 1996). 
CDKN2A is homozygously deleted or mutated in a large p ro-
portion of tumor cell lines (e .g . Kamb et al, 199 4a; Nobori et al, 
1994; and review ed in P ollock et al, 1996) , includin g those derived 
from m elanomas (e .g. C airns et al, 1995; and review ed in Pollock et 
a/, 1996); however, the frequen cy o f intragenic mutatim) or 
deletion is considerably lower in uncultnred melan om as (Gruis el a/, 
1995; Flores eta/, 1996; H ealy el a/, l996; Maelandsmo el a/, 1996; 
Ohta et al, 1996; Platz et al, 1996). M oreover, germline mutations 
have been found in several m elanoma-prone fam ilies (e .g. H ussus-
sian et a!, 1994; Ka mb et a/, 1994b; a11d reviewed in Haywar d, 
1996) . In addition to dele tions and mutations, o ther mechanism s of 
inactivation of CD KN2A are m ethylation of the promoter region 
(Gonzalez-Z ulue ta et al, 1995; H erman et al, 1995; M erlo ct al, 
1995) and post-transcriptional silen cing (Okamoto et a/, 1994; 
Musgrove el a/, 1995; Yeager et a/, 1995; N aumann el a/, 1996; 
Srivenugopal and Ali-Osman , 1996; C astellano eta/ , submitte~)-
Introduction of CD KN2A into various human tumor cell hn es 
has been reported previously with the exception of melanoma cell 
lines, the most relevan t cell type bio logically. R estoration of p1 6 
expression (almost invariably at extrem ely high levels) i~1 d~a::e~ent 
tumor lines has been sh own to lead to cell growth mlu bitJon, 
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measured in various ways : by fluorescence-activated cell sorter 
analysis, showing a G1 phase accumulation of the transfected cells 
(]in eta/, 1995; Lukas et al, 1995; Medema et al, 1995; QueUe et al, 
1995; Shapiro et al, 1995; Fueyo et al, 1996); by cell culture 
methods, yie.lding a decrease in cell numbers (Arap et a/, 1995; 
Shapiro et a!, 1995) or in colony-forming efficiency (Guan et a/, 
1994; Spillare et al, 1996), or a decrease in growth rates over a 
period of 6-12 d after adenovirus-mediated CDKN2A expression 
(]in et al, 1995; Fueyo et al, 1996); and by DNA synthesis 
measurements, showing a decrease in eH]thymidine (Tenan et al, 
1995; Hengstschlager et al, 1996) or bromodem,)'uridine incorpo-
ration (Lukas et al, 1995; Serrano et al, 1995) . Reintroduction of 
CDKN2A has also been reported to inhibit cloning efficiency in soft 
agar in a glioma cell line (Fueyo et al, 1996) and to inhibit 
tumorigenicity in 1nice of a colon carcinoma cell line (Spill are et. al, 
1996) and a non-small cell lung carcinoma (NSCLC) cell line (]in 
et al, 1995) . These effects ofCDKN2A/p16 have been shown to be 
dependent on the presence, in the recipient cell line, of functional 
pRB (Guan et al, 1994; Lukas et al, 1995; Medema eta/, 1995; 
Serrano et al, 1995; Hengstschlager et al, 1996; Spillare et al, 1996). 
On the basis of this information, we decided to investigate the 
effects of reintroducing wild-type (wt) p16, at levels similar to those 
of cultured neonatal foreskin melanocytes, into a melanoma cell 
line that nom1ally does not express the protein. We chose MM96L, 
a lightly pigmented, fast-growing fu1e, as our model cell line. Tllis 
cell line was derived from a lymph node metastasis of a 66-y-old 
female (Wllitehead and Little, 1973; Pope et al, 1979). MM96L 
does not express p16 protein, even though it still retains a wild type 
(wt) CDKN2A allele and transcribes mRNA for CDKN2A. Inac-
tivation of tllis gene in this cell fu1e occurs via a novel mechanism 
of post-transcriptional silencing (Castellano et al, submitted), also 
reported by others in different tumor types (Okamoto et al, 1994; 
Musgrove et al, 1995; Yeager et al, 1995; Naumann et al, 1996; 
Srivenugopa1 an.d Ali-Osman , 1996). Tllis cell line expresses func-
tional pRB (Pedley et al, 1996) and has been shown previously to be 
able to form colonies in soft agar (Sheridan and Simmons, 1981; 
Sheridan et al, 1984) and to be tumorigenic in mice (Parsons et al, 
1991). 
MATERIALS AND METHODS 
Cell Culture and Clone Generation MM96L cells were provided by 
Dr. P.G. Parsons and were grown in RPMl 1640 + 5% fetal bovine serum 
(FBS). Transfectants were grown in RPMI 1640 + 1 0% FBS and 800 11-g 
G418 per ml. Clones were generated by trypsinizing a wt p16(148)-
transfected population, after removal of the largest colonies by gentle 
suction with a Pasteur pipette, in order to enrich for dendritic, p16-
expressing cells, and by plating the cell suspension by limiting dilution in 
96-wcll plates. Anti-sense (AS) CD.KN2A-transfected cells were plated by 
limiting dilution without the enrichment step. Cells were refed evety week 
by removing half the medium and replacing it with fresh medium. Mter 
about 6 wk, 57 clones were trypsinized and plated in small flasks. Cells were 
harvested when confluent; half of each clone was lysed for protein extract, 
and the other half was stored in liquid nitrogen. Experiments shown here 
were performed on cells thawed and cultured for less than 10 passages. 
Neonatal foreskin melanocytes were cultnred in RPMI-1640 + 10% FBS 
supplemented with 0.6 JLg cholera toxin per ml and O.l 11-g 12-0-
tetradecanoylphorbol-13-acetate per mi. 
Plasmids and Transfections The wt pl6(148) eDNA was a gift from 
Dr. D. Beach. Wt p16 (148), wt p16(156), and variru1t (mutation Pro81Len 
ru1d polymorphism Ala148Thr) p16 cDNAs were subcloned into a modified 
version of pOP13CAT expression vector (Stratagene, La Jolla, CA), 
in which the chloramphenicol acetyl transferase cassette was replaced by a 
multiple cloning site. Tbis generated pOP13p16(148)wt, pOP13p16(156)wt, 
pOP13p16 mut4, and pOP13p16 mut8, w hich contained the cDNAs for 
p16(148), p16(156), mutation Pro81Leu , and polymorphism Ala148Tiu, 
respectively. pOP13p16AS was generated by subcloning wt p16(148) in the 
3' -5' orientation. Trru1sfectiou was performed by elec troporation in a BTX 
ElectroSquarePorator (BTX, San Diego, CA) under the following condi-
tions: 107 cells in 200 11-l RPM£ 1640 + 10'Vo FBS were pulsed at 250 mV for 
20 msec. Electroporated cells were plated in RPM! 1640 + 10% FBS , and 
800 p.g G418 per ml were added 24 h after transfection. 
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Table I. Transfection of CDKN2A" Results in a Decrease 
in Colony Counts" Compared to an Anti-Sense Control 
Constrnct 
p16(148)wt 
p16AS 
Experiment #1 
8.1 ::!: 4.7 
53.1 ::!: 6.0 
Experiment #2 
19.2 ::!: 8.4 
51.2 ::!: 10.5 
"MM96L cells were transfected with p0P13p16(148)wt or p0Pl3p16AS, as 
indicated in the text. After 2 wk selection in G418, colonjcs were counted and cells 
were photographed (Fig 1). 
" A grid (1 X l em squar es) was appHed to the back of each fla sk, and eight colony 
counts were performed in rand01nly chosen squares. Values are the me~ms for these 
counts ± SD (tvvo independent experiments). 
Western Blotting Cells (106) were harvested and lysed in N ETN (20 
mM tris(hydroxymethyl)aminometlmne, pH 8.0, 1 mM ethylenediamine 
tetraacetic acid, pH 8.0, 100 mM NaCI, 5 11-g leupeptin, pepstatin, and 
aprotinin per ml, 0.5 mM phenylmethylsulfonyl fluoride, and 0.5% NP40) 
supplemented with 300 mM NaCI. Protein lysate (25-50 JLg) was separated 
by 15% sodium dodecyl sulf.,te-polyacrylamide ge l electrophoresis and 
electrotransferred to polyvinylidene difluoride membrane. The filter was 
blocked in 5% BLOTTO for :2: 1 h, probed with either anti-p16 antibody 
(Wang ct al, 1996) , anti-CDK4 antibody (Santa Cruz Biochemical, Santa 
Cruz, CA), anti-p21/W AF1 monoclonal antibody (Oncogene Science, 
Manhasset, NY), or anti-proliferating cell nuclear antigen antibody (No-
vocastra Laboratories, N ewcastle upon Tyne, UK), washed in phosphate-
buffered sa line-Tween 20, repro bed with a secondary antibody, and, after 
extensive washing, developed using enhanced chemilurninescence method-
ology according to the manufacturer's instructions (DuPont-NEN, Boston, 
MA) . 
Imrnunoprecipitation One milligram of protein lysate fi·om each clone 
was mixed with 30 JLI of a 50% suspension of anti-p16 antibody conjugated 
to Protein A-Scpharose and incubated for at least 1 h at 4°C on a rocker. 
The inununoprecipitate was then pelleted, washed three times in NETN, 
and finally resuspended in 100 JLl of 1 X protein loading buffer (5 X : 4.2 g 
tris(hydro,.:ymethyl)aminomethane base, 10 mi glycerol, 15 g sodium 
dodecyl sulfate, in 75 ml H 20, pH 6.8, 0.01% bromophenol blue and 25% 
{3-mercaptoethanol), and denatured by boiling. Thirty microliters were 
loaded onto lanes of a mini-gel. 
Cell Growth Exponentially growing cells (2 X 10'1) were plated in 
triplicate wells in 24-well plates for each clone and each time point to be 
cow1ted. Each day for 3 consecutive days, cells fi·om one plate were 
trypsinized and counted. 
Soft Agar Cloning Exponentially growing cells (5 X 104) were plated in 
triplicate in a six-well plate in a suspension ofRPMl1640 + 10% FBS + 800 
JLg G418 per ml ru1d an equal volume of 0. 7% agar (Difco, Detroit, MI), 
over a layer of 0.5% agar/medium. Cells were grown for 2-3 wk, and 
colonies (> 50 cells) were counted under a dissection microscope after 
fncing in 100% methanol and air dtying. 
RESULTS AND DISCUSSION 
Amino Termini p16 Variants Are Functionally Equivalent 
The i11itial description of p16 as a CDK4-binding protein involved 
a 148-anrino acid protein (Serrano et al, 1993) . Later studies 
reported the presence of an upstream metluonine, whi ch made p16 
156 amino acids long (Hmmon and Beach, 1994; Okamoto et al, 
1994) . It has been shown previously (Serrano et al, 1993; Parry and 
Pete rs, 1996) that both these forms of p16 are abl~ to bind <md 
inhlbit CDK4 and CDK6 and are therefore regarded as functionally 
active. Tllis study was performed with the first reported eDNA, 
wluch will be referred to as wt p16(148), except w h en specified 
otherwise (wt p16(156)). 
Transfection of CDKN2A Results in Two Morphologically 
Distinct Populations After transfection and 2 wk selection in 
G418, we observed that tl:~e wt p16(148) transfected cel.ls formed 
colo11ies at about 15-38% the efficiency of cells transfected with an 
anti- sense p16 (p16AS) construct (Table I), in keeping with simil<u 
observations by other groups (Guan et a/, 1994; Arap et al, 1995; 
Serrano et al, 1995), and providing further evidence that plU3 is 
functional in MM96L. C lose inspection of the p16-transfected cells 
revealed two morphologically distinct populations: one that formed 
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co lonies indistinguish able fro m th!! cells transfected with e ither 
p16AS or vector alone, and one that was very dendritic, grew quite 
sparsely, and contained a number of large multinucleate cells (Fig 
lA,B) . In general , only the large, highly dendt~iti c cells contained 
multiple nuclei du e to a defect of cytokin esis. T hese cells were lost 
upon passaging, as they presumabl y represented a terminal pheno-
type. T he colony-fanning population was G418 resistant but pl6 
negative, whereas the dendt;tic population was p1 6 positive, as shoWJ t 
by double immunofluorescence staining with anti-p16 an tibody and 
CO Lmterstaining with an anti-tubulin antibody (Fig 1C,D). As shown 
in the fi gure, cells with moderate to !ugh levels of p1 6 expression were 
dendritic and stained uniformly throughout the nucleus and cytoplasm, 
whereas cells v,rith low or undetectable levels of p1 6 e:>..-pression were 
mostly row1ded and indistinguishable liom the control. T he few low 
level expressing cells displayed only nuclear staining for p16 . This 
experiment was repeated ftve times both with wt p16(1 48) (Serrano el 
nl, 1993) and with wt p1 6(1 56) (Hannon and Beach, 1994; Okamoto 
et nl, 1994), with compm:able results (data not shown). 
Tra nsfection of a eDNA encoding a mutant p1 6 (Pro81Leu), 
which produces an utactive proteiJ1 in terms of CDK4 binding 
(Ranade et nl, 1995), yielded onl y the rounded , colony-forming 
cells as with the p 16AS construct, whereas transfection of a benign 
polymorphic variant of pl 6 (A.la148Thr) , which re taU1S CDK4 
binding (Ranade et a/, 1995), yielded the same two populations as 
wt p1 6(156) (Fig lE,F) . Transfection of wt p1 6(156) in a second 
melanoma cell tine, SK-MEL-1 3, which has a homozygous deleti on 
of C DKN2A , resulted in the same dendritic and colony-forming 
populations (Fig lG,H). T hese data indicate that re in troduction of 
wt p 16 has an effect on the m orphology of the cells that e}..-press the 
proteiJ1. T l:lls effect is not cell-line specific, and it is abolished by 
mutations that abrogate p16 fun ction. 
Morph ologic chan ges in CDKN2A-tTansfected cell populations 
ha ve been previously reported by o thers. Shapiro et nl. (1995) , in 
their study on NSCLC cell lines, obse rved a flattening of the cells, 
which was described as a less transformed phenotype. T he sa me 
was observed in gliom a ce lls (Fueyo et nl, 1996), where the 
presen ce of a cell population iudi stingui shable fi·orn control cell s 
(noninfected) was also reported. Enlarged and o ften multinucleated 
cells were also observed by Spillare el a/. (1996) in th eir study of 
colon carcinoma cell lines . T he appearance of a G418-resistan t, 
p16-nega ti ve, colony-forming population is expected in transfec-
tions with a tlLmor suppressor gene because selective pressure 
would, iJ1 our case, be against the cell s expressu1g wt p1 6 prote in . 
Clonal Cell Populations Vary in the Level ofp16 Expression 
To further investiga te the consequences of reintrodu ction ofwt p16 
in to MM96L cells, we established clonal populations. N on e of the 
large, very dendritic and mul tinuclear cells present in the origin al 
selected population (e.g., Fig lA) were represented in the few 
p1 6-positive clones obtau~ed. Of 57 clones established, on ly niJ1e 
were positive for p16 by western blot analysis, and the levels ofp16 
expression were variable and ranged betw een 3- and 70-fold lower 
in comparison with H eLa cells (Fig 2A). T he p1 6 levels obtained in 
the maj ority of the transfected clones were comparable to th ose 
expressed by cul tured neonatal foreskin melanocytes (Fig 2B) . Al.l 
nine clones showed a dendritic morphology (examples of which are 
sho wn in Fig 3A-D) , altho ugh the degree vari ed between clones. 
Three clones (1A9, 3A3, 4B8b) transfected with wt p1 6(148) were 
further analyzed in this study aud were chosen, on the basis of the 
levels of p1.6 expressed, to represent a cross-section of the whole 
range (Figs 2 , 3). O ne clone transfected with an ti-sense CDKN2A 
(ASF3) was chosen as a contro l because the re were no differences 
either u1 morpho logy or growth rates between anti -sense- trans-
fected cells and empty vector-transfected cells (results no t shown). 
ltnmunofluorescent staining of the three expressi.n g clones showed 
that th e p 16 staitun g was unifo rm throughout the cell , ""i th no 
eviden ce of specific subcellular compartmentation (data not shown, 
see fo r example Fig 1C) . 
Growth Rate Is Significantly Reduced in p16-Expressing 
Clones Growth of the three CD KN2A- transfe cted clones was 
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co mpared to th at of ASF3 in three i.ndependent experi men ts (Fig 
4) . Each of the three pl6-rrm1sfected clones grew slower than ASF3 
by day 3 (p < 0.05 in each case) bu t did not vary to a significant 
degree w ith respect to each other . T hus, levels of wr p 16 expression 
did nor correlate with growth rate, inasmuch as 4B8b did not grow 
slower than lA9 or 3A3, even thougl1 its p1 6 expression levels were 
the highest (Fig 2 and Fig SA) . One possibl e e:>..-planation for this 
was suggested by the analys is ofCDK4 levels. As shown in Fig SB, 
the levels of C DK4 expressed in the va ri ous clones appea red to be 
subj ect to a degree of clonal variation , and, sttikin.gly, clone 4B8b 
had the highest levels of DK4, 2- fo ld more than the ASF3 control 
and 6-fold m ore th m1 clone 1A9. T lus suggests that the !ugh levels 
of p16 expression in 4B8b are compensated for by the concomi-
tantly !ugh levels o f CDK4 and could explain why the lugher 
expression of p16 does no t induce a more dramatic effect on cell 
growth rate in this line . 
Immunodepletion of p 16 and its associated proteins fi:om cell 
lysates of the tlvee clones showed that in each cell line, even 4B8b, 
the maj o1ity of CDK4 and CDK6 was not associated witl1 p16, 
indicating that th e levels of p1 6 expressed were not sufficient to 
ti trate out CDK4 and CDK6 in these clones, even though the levels 
were close to those observed in cul tured neona tal foreskin mela-
nocytes (Fig 2). We propose that strong overexpression of p16 
dete rmin es cell cycle arrest in Gl and eventu ally cell death, as 
reported by o~h ers (Guan et nl, 1994; Arap ef nl, 1995; Jin et a/, 1995; 
.Lukas et of, 1 995; M edem a eta/, 1995; QueUe et nl, 1995; Serrano d 
nl, 1995; Shapiro et nl, 1995; Tenan et nl, 1995; Fueyo et a/, 1996; 
H engstschlager el nl, 1996; Spillare el nl, 1996). T lus is most clearly 
demon trated by Fueyo et n/. (1996): the levels of adenovirus-
mediated expression ofp16 in gl.iom a cells exceeded that ofSaos-2 
cells, which express e levated levels of tit is protein , and the majority 
of cells were accumulated in GO/G 1 phase. O n the other hand, 
lower levels of p1 6 ex-pression , as obser ved in ou r clones, are 
permissive of cell cycle progression and growth, albeit at reduced 
rates. Analysis of the cell cycle dist1;bution of the fo ur clones by 
flu o rescence-acti vated cell sorter did not reveal any significan t 
di.lferences between the p16-tTansfected clones and the ASF3 
contro l (data not shown) . 
Expression ofpl 6 iJ1 these clones decreased with time in cu.l ture, 
and after 4 m onths was n ot detecta ble on a western blot even after 
extremely long exposures; the loss of expression correlated witl1 
attenuation of the dendtitic morphology, and with loss of growth 
rate dill:crences in these clones (data not shown). T his selective 
pressure in culture aga inst p16-expressing cell s was to be expected, 
and others have shown the same phenom enon (Tenan et nl, 1995). 
It also provides evidence that the m orphologic an d growth rate 
differences observed in the ea rl y passages of these clones were due 
to the expression of p1 6. 
Ability to Form Colonies in Soft Aga.r Is Not Altered b y p 16 
Expression C lones 1 A9, 3A3, 4B8b, and ASF3 were fiu:ther 
analyzed for the ir abilit)' to form colonies in soft agar assays. T he 
experi.ment was perfonned twice (each in triplicate), and bo th times 
the clones expressin g wt p16(148) were as efficien t as the anti-sense 
contro l in forming colonies in soft agar (Table II). In contrast, 
cloni.ng abili ty of pl6-u-ansfected glioma cell s has been reported to 
be decreased (Fueyo et nl, 1996). T his resltl t, however, may simply 
reflect the abili ty of hi gh levels ofp16 to u1hibi t cell growth , rather 
than ca use an intrinsic ch;utge in the anchorage-independent 
growth of the t.ran sfected cells. ft has been shown recently that 
several low tumorigenic and nonmetastatic melanoma cell lines 
carried homozygous deletions of CDKN2A or· lacked its expres-
sion, w hereas other metastatic melan oma cel.l lines did not exlubit 
abnormali ties in the CDKN2A gene (Luca ct nl, 1995). O ur data 
indica te that reintrod uction of wt p16 iJ1 a melanoma cell line at 
levels sunil ar to those expressed b y cultured melanocyti!S is not 
enough to reverse Rnchorage-independent g rowth. 
Melanoma-Associated Markers Are Not Altered in p16-
Expressing Clones T he m orphologic chan ges observed iJ1 the 
wt p 16 o·anstectants were suggestive of the cells undergoing 
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Figure 1. Marked morphologic differences between functional and nonfunctional CDKNZA transfectants. Light microscopy (LM) and 
immunofluorescence microscopy (IFM) photographs of stably tran sfected MM96L cells after 15 d selection in 800 ~-tg G4 18 per mi. (A) (LM) 
pOP13pl6(156)wt; (B) (LM) pO P13pl 6AS; (C) (IFM) p0Pl3pl 6(156) wt, p16 staining; (D) (JFM) tuhu lin staining on same fie ld as (C); (E) (LM) 
pOP13p16(AJa148Thr); (F) (LM) pOP13p16(Pro81Leu). --'> in (A) and (E) point to the two morphologically different populations. Light tnicroscopy (LM) 
photographs of stably transfected SK-MEL-13 cells afte r 15 d selection in 800 jJ.g G418 per ml (G) (LM) p0Pl3pl6(156)wt, dendritic population; (H) (LM) 
pOP13p16wt, colony-forming population. Scale bar for (A), (B) , (E) , (F) , (G) , and (H), 100 ~-tm . Scale bar for (C) and (D), 10 ~-tm. 
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Figure 2 . p16 expression levels vary between the different 
CDKN2A-transfected clones. (A) HeLa cell s and nine MM96L clones 
transfccted with wt pl6(l48) were lysed; 50 J.Lg of protein lysate were nu1 
on a 15% polyacrylamide ge l and immunoblottcd widt anti-p1 6 antibod)' · 
(B) Equal numbers ofHeLa ce lls and cultured neonatal foreskin melanocytes 
were lysed, nm on a 15"!.> polyacrylamide gel and immnnoblotted with 
an ti-p 16 antibody. 
differentiation . Since the appearance of the cells was reminiscent of 
adu lt melanocytes (Houghton eta/, 1982), the clones were assessed 
to determine whether the dendritic phenotype was associated with 
the appearance of melanocyte- associated markers or the loss of 
melanoma-specific markers. We first analyzed p21 / WAF11CIP1 
expression levels by western blotting becau se it has been shown 
that p21 expression is elevated in melanoma cells induced to 
tenninally differentiate Qiang ef a/, 1995) . MM96L cells normally 
express extrem ely low levels of p21 protein, and we were unable to 
detect an increase in any of the transfected clones (data not shown) . 
We then analyzed tyrosinase-related protein 1, a melanosomal 
antigen identified with monoclonal antibody B8G3 (Takahashi and 
Parsons, 1992); HMB45, an antigen present on melanomas and 
junctional nevus cells but not on intraderm al nevus cells or normaJ 
ad ult melanocytes (Gown et a/, 1986); and intermediate filament 
antigen, which is differentially expressed in normal m elanocytes 
plG AL TEit S MORPHOLOGY AND GROWTH IN MELANOMA 65 
and in melanomas (Pruss ef a/, 1981). No consistent change in the 
expression patten~ of these markers was observed, and the differ-
ences between clones were equivalent to the clonal variatiori seen 
norma lly in the MM96L cell line (data not shown). Taken together, 
these data indicate that reintroduction of wt p16 causes the 
selection of cells with a dendritic phenotype and a slower growth 
rate but is not associated with changes in melanoma markers or 
markers th;Jt have been associated with terminal differentiation in 
melanoma cells. 
Conclusion High levels of expression of p16 in melanoma cells 
can cause gross changes in morphology, cell cycle arrest, and cell 
death as exemplified by colony-fanning eB:Iciencies. In rare cases, 
clones can be obtained that are able to grow. T hese clones el\.'Press 
levels ofp16 comparable to cultured neonatal foreskin melanocytes 
and exhibit an altered m orphology and a significantly lower growth 
rate compared to controls but do not lose their ability to form 
colonies in soft agar. Willie the significance of the altered mor-
phology is unclear, these findings indicate that p1 6 can act as a 
growth suppressor. Our data also suggest that reintroduction ofp16 
in m elanoma cells at roughly the levels expressed by cultured 
melanocytes is insufficient to reverse anchorage-independent 
growth ability, a marker of ttunorigenic potential. 
Recent publications ha ve suggested CDKN2A's involvement in 
cellular sen escence. P16 expression seems to be n ecessary for a cell 
to enter the senescence pathway (Alcorta eta/, 1996), and its loss is 
associated with extended i11 11i1ro proliferative potential (Noble eta/, 
1996) but is insufficient for immortalization (Loughran et a/, 1996; 
Noble eta/, 1996). T hese o bservations support the idea that loss of 
CDKN2A is a necessary growth advantage for the cell on the path 
to immortalization, but other events are needed as well. Our 
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l'igure 3. Morphology of four CDKN2A-transfected MM96L clones . Ligh t microscopy photographs of clones obtained by ljmi ting dilution plating of 
the transfectcd cell population. (A) clone 1 A9; (B) clone 3A3; (C) clone 4138 b; (D) clone ASF3. Clones were transfectcd with pOP13p16wt(148) (A-- C) or 
with pOP13p16AS (D) . Scale bnr, 1.00 J.L111. 
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Figure 4. The three CDKNZA-transfected clones grow slower than the ASF3 control (refer to Fig 3A-D). Cells (2 X 1 04 ) were plated in o:iplicatc 
for each clone. Cells were trypsinized and counted for 3 consecutive days . Cell counts of day 1 were considered 100%, and cell coun ts of days 2 and 3 were 
expressed as a percentage of cell numbers at day 1. The averages of the percentages of the three experiments are reported for each time point. and bars 
represent SEM. Nine observations were made for each point. Va lues at day 3 are significantly different between p16-transfected clones and ASF3, with p < 
0.05 in all cases. When error bars arc not shown, the SEM is within the width of the point symbol. 
observations and others (Tenan et al, 1995) that loss of p16 
expression is selected for in cultured ceUs over time also support 
these data. The higher frequency of CDKN2A inactivation in 
cultured cell lines compared to fresh tumors could also reflect this 
phenomenon. Failure to revert phenotypic markers of tumorigenic 
potential by reintroduction of CDKN2A couJd be due to the fact 
that p16 loss .is necessary but not sufficient for immortalization. 
Restoration of CDKN2A into other cell types has been per-
formed previously by others and has yielded different results 
compared to our analysis. In two instances, adenovirus-mediated 
expression ofp16 has been attempted in NSCLC cell lines Oin et al , 
1995) and i11 glioma cells (Fueyo eta/, 1996) . In both cases the cell 
lines chosen did not express p16, and its reintroduction caused a 
decrease in tumorigenic potential, as measured by tumor formation 
in nude mice and soft agar cloning efficiency, respectively. In both 
reports, levels of p16 expression were high, and expressing cells 
were not clonaL Jin et al (1995) showed that I-1460, the cell line 
chosen for the tumorigenicity assay, had its growth completely 
abrogated after Ad5p16 infection, which could, in fact, be the 
reason why no tumors grew in injected mice. Spillare et al (1996) 
reported the generation of a p16-positive colon carcinoma clone 
that was not tumorigenic in. nude mice. But they also showed a 
p16-positive clone that produced tumors that still expressed p16 
A p16 8 
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after resection from the host animaL These data indicate that 
CDKN2A expression is not in itself a suppressor of tumor forma-
tion . 
Differences in the effects of CDKN2A reintroduction may also be 
ascribed to differences in the recipient cell lines . In fa ct, studies on 
RB1, the prototype of tumor suppressor genes, have shown that the 
effect of reintroducing it into RB1 negative cell lines can vary 
depending on the cell type chosen . Reintroduction in retinoblas-
toma cells causes morphology changes, reduction of growth rates, 
decrease in soft agar cloning e ffici ency, and loss of tumor formation 
in nude mice (Huang et nl, 1988), w hereas restoration of _pRB 
function in prostate cancer cells does not affect growth rate and/or 
morphology but determines loss of tumor formation in mice 
(Bookstein et al, 1990). Moreover, an early study on Wilms' tlUllOr 
cells showed that reintroduction of chromosome 11 abl ated tumor-
igenicity in nude mice and decreased the ability to grow in soft agar 
but did not alter cell morphology or other growth parameters 
(Weissman et al, 1987). In this respect, if a tumor su_ppmssor gene 
is defined by its ability to inJubit anchorage-independent growth 
and tumor formation in experimental a.tumaJs, then we shou ld 
conclude that CDKN2A does not behave like a classic tumor 
suppressor, at least in mela.t10ma cells . Tlus is supported by the 
studies of Reed et al (1995), who analyzed pl6's expression by 
CDK4 c PCNA 
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Figure 5. Levels of p16 and CDK4 proteins in CDKNZA-transfected clones (refer to Fig 3A-D). A western blot of clones 1A9, 3A3 , 4B8b, :u1d 
ASF3 was probed with: (A) anti-p16 antibody; (B) anti-CDK4 antihody; (C) anti-proliferating cell nuclear antigen antihody. T he exposed film was then 
ana lyzed by densitometer, and signal intensities were quantified in arbitrary units and reported on the y axis . The x axis is, in aU cases, 1 = clone 1 A 9: 2 = 
clone 3A3; 3 = clone 4B8b; 4 = clone ASF3 . Probing with anti-proliferating cell nuclear antigen antibody as a control showed approximately equal lane 
loading. Comparison of proliferating cell nuclear antigen levels between asynchronous cell populations is considered to reflect cell numbers because the cell 
cycle distribution of the cells is similar. 
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Table II. Reintroduction of CDKNZA in Melanoma Cells 
Does Not Inhibit Anchorage-Independent Growth" 
Clone Experiment 1 Experiment 2 
1A9 19.1 ± l.2 31.0 ± 3 .7 
3A3 18.8 ± 1.5 28.1 ± 2.1 
4B8b 23.0 ± 1.4 28.0 ± 3.4 
ASF3 23 .0 ± 3.0 29.4 ± 1.2 
"Numbers represent number of colonies growing in a 2 X 2 mm square (400/wcll) . 
Number:! arc averages of five squares/well for trlp lkatc wdls; st:mda.rd deviation is 
calculated for the triplicates (mean :!: SD). 
average per square X 400 
C lonin g efficiency = 4 X I 00 . total number of cells plated (5 X 10 ) 
C loning efficiency range for experiment 1: 15.2-18.4%. C lonin g efficie ncy range for 
experiment 2: 22 .2-24.8% 
immunohistochemistry in 103 melanocytic lesions representing all 
stages i.n the progression of melanoma. Their results suggest that 
loss of p16 expression is not necessary for tumor initiation, because 
a]] in situ melanomas and the majority of primary invasive m elano-
mas retain expression of this protein . They propose that loss of p 16 
expression may be important for the tumor's ability to metastasize. 
In view of these results, reintroduction of CDKN2A i.n m elanoma 
cells would not be expected to revert any of the markers of 
tumorigenicity, incl uding an chorage-independent growth. In con-
clusion, we propose that CDKN2A/p16 is a growth suppressor, but 
not a tumor suppressor, as defined by classical assays. 
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